Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | TACR2 | P21452 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SHBG | P04278 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TST | Q16762 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809524 | 0.98 | ESR1 (0.52) | ACHEESR1ADRA2AADORA3TACR2 | |
| Dodecylacetate SCHEMBL28973893 | 0.92 | ALDH1A1 (0.65) | ACHEESR1ADRA2AADORA3TACR2 | |
| SCHEMBL3675245 | 0.86 | CTDSP1 (0.49) | KDM4EALDH1A1LMNAPTGS2TNKS2 | |
| SCHEMBL2387794 | 0.85 | NPC1 (0.57) | ESR1KDM4EALDH1A1CALM1F13A1 | |
| SCHEMBL1263885 | 0.85 | HRH4 (0.44) | ALDH1A1LMNAPTGS2TNKS2 | |
| SCHEMBL1263483 | 0.85 | HRH4 (0.44) | ALDH1A1LMNAPTGS2TNKS2 | |
| SCHEMBL2310305 | 0.85 | HRH4 (0.44) | ALDH1A1LMNAPTGS2TNKS2 | |
| SCHEMBL16673001 | 0.84 | CTDSP1 (0.50) | KDM4EALDH1A1LMNACYP3A4TNKS2 | |
| SCHEMBL15529361 | 0.84 | LMNA (0.59) | ALDH1A1LMNA | |
| SCHEMBL1345319 | 0.84 | LMNA (0.59) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | SALUTRIA PHARMACEUTICALS LLC | 2012-11-22 | — | — | US | disclosed |
| US-8252840-B2 | administering monoesters of probucol, such as AGI-1067, succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | PNLIP, SLC5A2, LIPC | ACHE 4226/4885ESR1 4443/4885ADRA2A 2920/4885 |
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | PNLIP, SLC5A2, LIPC | ACHE 4226/4885ESR1 4443/4885ADRA2A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.